SOURCE: The Bedford Report

The Bedford Report

April 28, 2011 08:16 ET

Advanced Cell Technology and Curis Show Strong Growth Potential

The Bedford Report Provides Analyst Research on Advanced Cell Technology & Curis

NEW YORK, NY--(Marketwire - Apr 28, 2011) - There is plenty of optimism surrounding the biotech sector as firmer pricing and new products have improved sales and earnings trends. Meanwhile, younger, more speculative firms continue to garner significant attention with potential blockbuster products working their way through the regulatory process. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides research reports on Advanced Cell Technology, Inc. (OTCBB: ACTC) and Curis, Inc. (NASDAQ: CRIS). Access to the full company reports can be found at:

www.bedfordreport.com/2011-04-ACTC

www.bedfordreport.com/2011-04-CRIS

IMS Health, a leading research and analytical firm serving the pharmaceutical and medical industries, projects an increase in worldwide biotech growth in 2011 of between 5 and 7 percent, with a similar outlook stretching out to 2015. Emerging markets such as China, India, and Brazil are expected to contribute significantly to this growth. Sales growth of 15 percent is forecast in emerging markets, many of which are benefitting from increased government spending on healthcare and broader private health coverage for workers.

The Bedford Report releases regular market updates on the Healthcare Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

Advanced Cell Technologies recently won regulatory approval from a European Medicines Agency's Committee for late-stage human trials of therapies using human embryonic stem cells. Last month Advanced Cell Technology said it ended 2010 with cash and cash equivalents of $15.9 million and less than $1 million of debt, compared to $2.5 million in cash and cash equivalents and $8.4 million of debt in the year-earlier period.

Curis is a drug development company that is committed to leveraging its "signalling pathway" drug technologies to seek to create new targeted small molecule drug candidates for cancer. Earlier this month shares of Curis surged following a presentation at a cancer conference in Orlando. Investor interest centers on promising data showing that Curis' technology platform may have use in battling a wide variety of different cancers.

The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer

Contact Information